Khan, O A <br/><br/>
A prospective, open-label treatment trial to compare the effect of IFN beta-1a (Avonex), IFNbeta-1b (Betaseron), and glatiramer acetate (Copaxone) on the relapse rate in relapsing-remitting multiple sclerosis.  [electronic resource] 

 -  European journal of neurology  Mar 2001 
 - 141-8 p.  digital 
<br/><br/> Publication Type: Clinical Trial; Comparative Study; Journal Article 
<br/><br/><label>ISSN: </label>1351-5101 
<br/><br/><label>Standard No.: </label>10.1046/j.1468-1331.2001.00189.x  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adjuvants, Immunologic--therapeutic use<br/>Adult<br/>Female<br/>Glatiramer Acetate<br/>Humans<br/>Interferon beta-1a<br/>Interferon beta-1b<br/>Interferon-beta--therapeutic use<br/>Male<br/>Multiple Sclerosis, Relapsing-Remitting--drug therapy<br/>Peptides--therapeutic use<br/>Prospective Studies<br/>Recurrence<br/>Severity of Illness Index<br/>Treatment Outcome